Install
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
- 283,131articles · 365d
- 1+ hour agolatest article
- Sep 13, 2025earliest in window
- 9%with images · 12,383 videos
- 293avg words
- business 172,973
- stocks 118,593
- markets 111,386
- investing 92,513
- stock market 91,194
- business news 75,977
- stock 71,324
- investment 70,384
- stock market news 67,193
- finance 56,890
- technology 54,616
- investment advice 53,947
- companies 49,938
- online trading 49,175
- online investment 43,597
- artificial intelligence 39,108
- online stock trading 37,086
- financial 31,432
- ai 29,693
- inc 20,543
- Economy, Business & Finance 248,798
- Finance & Business 235,620
- News 129,761
- Finance 70,469
- Business & Industrial 29,091
- Health & Wellness 11,551
- Science & Technology 9,383
- Medical 8,069
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
1+ mon, 1+ week ago (771+ words) Editas Medicine EDIT incurred a loss of 15 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 30 cents. The company had reported a loss of 63 cents per share in the year-ago quarter....
Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials
2+ mon, 3+ week ago (893+ words) ALAMEDA, Calif., June 18, 2026--Scribe awarded more than $25M from CIRM to accelerate additional CRISPR-based gene editing therapies for cardiometabolic disease into clinical trials Oops, something went wrong U.S. markets close in 6h 21m Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional…...
Google News
4+ mon, 3+ week ago (11+ words) EXALTA Strengthens MedTech Development with ISO 17025 Microbiology Laboratory Accreditation Yahoo Finance...
Ocugen Index Addition Highlights Rising Attention And Ongoing Gene Therapy Risks
5+ mon, 2+ week ago (469+ words) Ocugen, Inc. (NasdaqCM:OCGN) has been added to the S&P Biotechnology Select Industry Index. This index inclusion marks a new milestone for the company within the biotechnology sector. Ocugen focuses on biotechnology, with programs that seek to address eye…...
BRAIN Biotech has Been Granted a Key Patent for Its CRISPR-BMC Genome-editing Technology
5+ mon, 2+ week ago (192+ words) Newly patented CRISPR nuclease exhibits high activity in various prokaryotic and eukaryotic organisms Patent now opens up significant potential for further commercial use through licensing BRAIN Biotech offers its technology for strain optimization in customers' production strains Precise genome editing…...
Apellis Pharmaceuticals Details SYFOVRE, EMPAVELI Growth Plans and FcRn Gene-Editing Push at TD Cowen Conf.
6+ mon, 1+ week ago (859+ words) Apellis laid out a three‑pillar plan focused on a “durable” SYFOVRE franchise in geographic atrophy, an expanding EMPAVELI launch in nephrology, and a planned second‑half clinic entry for a Beam collaboration on an FcRn gene‑editing “once‑and…...
CRISPR Therapeutics touts zugo-cel CAR-T gains, eyes autoimmune expansion at Citi oncology summit
6+ mon, 3+ week ago (505+ words) CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows Chief Executive Officer Sam Kulkarni said the company is active across multiple disease areas, including a commercial product in sickle cell disease and thalassemia with Vertex, cardiovascular programs, an autoimmune “franchise…...
Eli Lilly Trial Wins And Gene Editing Progress Versus Current Valuation
6+ mon, 3+ week ago (338+ words) Eli Lilly (NYSE:LLY) reported successful results from the TOGETHER-PsO Phase 3b trial combining Taltz and Zepbound for patients with psoriasis and obesity. The company reached a second key milestone in its CRISPR-based gene editing collaboration with Scribe Therapeutics. The LIBRETTO…...
Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors
6+ mon, 3+ week ago (694+ words) SOUTH SAN FRANCISCO, Calif. & MADISON, Wis., February 18, 2026--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and the University of Wisconsin (UW) School of Medicine and Public Health today announced an expansion of their partnership to support clinical production and…...
Eli Lilly Advances Gene Editing And Lung Cancer Programs With Valuation Upside
6+ mon, 3+ week ago (400+ words) Eli Lilly (NYSE:LLY) reached a second milestone in its CRISPR gene editing collaboration with Scribe Therapeutics, advancing programs in neurological and neuromuscular diseases. The company reported positive topline Phase 3 LIBRETTO-432 results for Retevmo in RET fusion positive early-stage non…...